1. Burdick R, Coffey T, Gutka H, Gratzl G, Conlon HD, Huan C-T, et al. Statistical approaches to assess biosimilarity from analytical data. AAPS J. 2017;19:4–14.
https://doi.org/10.1208/s12248-016-9968-0
.
2. U.S. FDA. Guidance for industry (draft): statistical approaches to evaluate analytical similarity. September 2017.
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM576786.pdf
. Accessed 1 Feb 2018.
3. EMA. EMA/CHMP/138502/2017: Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development (draft). March 23, 2017.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/03/WC500224995.pdf
. Accessed 22 Jan 2018.
4. Tsong Y, Dong X, Shen M. Development of statistical methods for analytical similarity assessment. J Biopharm Stat. 2017;27:197–205.
https://doi.org/10.1080/10543406.2016.1272606
.
5. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7:335–45.